Connect Biopharma Holdings LtdCNTBEarnings & Financial Report
Connect Biopharma Holdings Ltd is a clinical-stage global biopharmaceutical company dedicated to developing innovative targeted therapies for inflammatory, immunological and autoimmune diseases. Its core pipeline includes candidate treatments for asthma, atopic dermatitis and other conditions with high unmet medical needs, with main operations across the U.S., China and key global markets to deliver effective therapeutic solutions to patients.
CNTB Q3 2025 Key Financial Metrics
Revenue
$16.0K
Gross Profit
N/A
Operating Profit
$-17.7M
Net Profit
$-17.2M
Gross Margin
N/A
Operating Margin
-110481.3%
Net Margin
-107500.0%
YoY Growth
N/A
EPS
$-0.31
Financial Flow
Connect Biopharma Holdings Ltd Q3 2025 Financial Summary
Connect Biopharma Holdings Ltd reported revenue of $16.0K for Q3 2025, with a net profit of $-17.2M (-107500.0% margin). Cost of goods sold was N/A.
Key Financial Metrics
| Total Revenue | $16.0K |
|---|---|
| Net Profit | $-17.2M |
| Gross Margin | N/A |
| Operating Margin | -110481.3% |
| Report Period | Q3 2025 |
Connect Biopharma Holdings Ltd Quarterly Revenue & Net Profit History
Connect Biopharma Holdings Ltd results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 2025 | $16.0K | — | $-17.2M | -107500.0% |
| Q2 2025 | $48.0K | -99.8% | $-12.9M | -26872.9% |
| Q2 2024 | $24.1M | — | $14.8M | 61.6% |
| Q2 2023 | $0 | — | $-30.5M | N/A |
Income Statement
| Q2 2023 | Q2 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $24.1M | $48000 | $16000 |
| YoY Growth | N/A | N/A | -99.8% | N/A |
Balance Sheet
| Q2 2023 | Q2 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Assets | $144.1M | $120.6M | $82.7M | $67.4M |
| Liabilities | $15.4M | $10.1M | $11.4M | $12.0M |
| Equity | $128.7M | $110.9M | $71.3M | $55.4M |
Cash Flow
| Q2 2023 | Q2 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Operating CF | $-31.2M | $-8.0M | $-12.6M | $-17.4M |